The global hospital acquired disease testing market size is expected to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to rising prevalence of pathogens in hospitals. Moreover, increasing morbidity rates owing to various infections is driving the market growth.
Hospital acquired infections (HAIs), also known as nosocomial infections, usually occurs to people in the emergency rooms or intensive care units. The ripening period of these infections vary from 48 hours to four days after the patient getting admitted in medical facility. The prime reason of spread of HAIs are lack of proper hygiene and rising multi-drug resistant organisms. Some of nosocomial infections include primary bloodstream infections, pneumonia, and urinary tract infections (UTIs).
In some cases, the nosocomial infections are traced to the patients’ own microbiome. This happens when patient’s upper skin layer comes in contact with possible threats, especially after surgical operations. The frequently-used techniques that are being used for preventing HAIs are solid-phase hybridization, PCR, and, microarrays. Government bodies are providing guidelines for the control & prevention of hospital acquired diseases in developing countries.
The report on the hospital acquired disease testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Hospital Acquired Disease Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Types (Methicilin-resistant Staphylococcus Aureus Testing, Urinary Tract Infection Testing, Bloodstream Infection Testing, Surgical Site Infection Testing, Pneumonia Testing, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Diatherix Laboratories Inc.; Life technologies; Qiagen GmbH; Nordion Inc.; Meridian Biosciences; Roche Diagnostics; Cepheid; Cantel Medical Corporation; and Others. |
Based on types, the market is segregated into methicilin-resistant staphylococcus aureus testing, urinary tract infection testing, bloodstream infection testing, surgical site infection testing, pneumonia testing, and others. The urinary tract infection testing segment is estimated to account for a key share of the market due to presence of advanced techniques to diagnose the hospital acquired diseases. On the other hand, the bloodstream infection testing segment is anticipated to expand at a rapid pace during the forecast period owing to rising number of government initiatives to control different types of HAIs.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to hold a large share of the market owing to various government regulations and growing healthcare infrastructure. On the other hand, the market of Asia Pacific is anticipated to expand at a healthy pace during the forecast period due to the growing medical tourism industry in countries such as India and China.
The global hospital acquired disease testing market has been segmented on the basis of
Key players competing in the hospital acquired disease testing market are Diatherix Laboratories Inc.; Life technologies; Qiagen GmbH; Nordion Inc.; Meridian Biosciences; Roche Diagnostics; Cepheid; Cantel Medical Corporation; and others.
The main market players are continuously indulging in the activities such as mergers and acquisitions, research and developments, investments for innovative products and collaboration to expand their market share.
The global hospital acquired disease testing market has been segmented on the basis of
Key players competing in the hospital acquired disease testing market are Diatherix Laboratories Inc.; Life technologies; Qiagen GmbH; Nordion Inc.; Meridian Biosciences; Roche Diagnostics; Cepheid; Cantel Medical Corporation; and others.
The main market players are continuously indulging in the activities such as mergers and acquisitions, research and developments, investments for innovative products and collaboration to expand their market share.
Some other reports from this category!